Home » FDA Agrees With AtheroNova’s Clinical Development Plan as Proposed
FDA Agrees With AtheroNova’s Clinical Development Plan as Proposed
AtheroNova has established a clear development plan, including Phase I and Phase II protocol outlines, based on the recently finalized minutes of its pre-IND meeting with the FDA for its AHRO-001, a compound for the treatment of atherosclerosis.
Yahoo! Finance
Yahoo! Finance
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May